Eicosapentaenoic acid and docosahexaenoic acid containing supplements modulate risk factors for cardiovascular disease: a meta-analysis of randomised placebo-control human clinical trials
AbuMweis S, Jew S, Tayyem R, Agraib L
Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 82 citations
How it was studied
- Design
- Meta-analysis (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- University or hospital
- Hashemite University
Based on 1 listed funder(s).
Publication
- Published
- 2017-07-04 · J Hum Nutr Diet · vol. 31 · issue 1 · pp. 67–84
- Publisher
- Wiley
- Cited
- 124 citations · more than 98% of similar papers · 6.9× the field average
- Impact
- Top 10% most cited in its field
- References
- 193 works
- Access
- Paywalled
- Research areas
- Fatty Acid Research and Health · Natural Products and Biological Research · Food Chemistry and Fat Analysis
- Keywords
- Medicine, Docosahexaenoic acid, Eicosapentaenoic acid, Internal medicine, Jadad scale, Blood pressure, Meta-analysis, Placebo, Triglyceride, Confidence interval, Cochrane Library, Lipid profile, Blood lipids, Gastroenterology, Cholesterol, Endocrinology, Fatty acid, Polyunsaturated fatty acid, Biochemistry, Pathology
- MeSH
- humans, cardiovascular diseases, docosahexaenoic acids, eicosapentaenoic acid, triglycerides, c-reactive protein, blood pressure, heart rate, dietary supplements, adult, aged, middle aged, female, male, hemodynamics, young adult
4 authors
From JO, CA
- Suhad Sameer AbuMweis · correspondingHashemite University
- Stephanie JewUniversity of Manitoba
- Reema TayyemUniversity of Jordan
- Lana M. AgraibHashemite University
Abstract
Background
Over 200 clinical trials have examined the effect of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplements on risk factors associated with cardiovascular disease. However, an updated analysis of the evidence is lacking. The aim of the present meta-analysis was to quantify the effect of supplements containing EPA and DHA on risk factors for cardiovascular disease.
Methods
An analysis was carried on 171 clinical trials with acceptable quality (Jadad score ≥3) that were identified from a comprehensive electronic search strategy of two databases (Pubmed and Cochrane Library). A random effect model was used to obtain an overall estimate on outcomes of interest. Heterogeneity between trial results was tested for using a standard chi-squared test.
Results
Compared with control, EPA and DHA supplements produced significant reductions of triglycerides of 0.368 mmol L-1 [95% confidence interval (CI) = -0.427 to -0.309], systolic blood pressure of 2.195 mmHg (95% CI = -3.172 to -1.217), diastolic blood pressure of 1.08 mmHg (95% CI = -1.716 to -0.444), heart rate of 1.37 bpm (95% CI = -2.41 to -0.325) and C-reactive protein of 0.343 mg L-1 (95% CI = -0.454 to -0.232). This analysis indicates an increase in both low-density lipoprotein cholesterol (mean difference = 0.150 mmol L-1 ; 95% CI = 0.058-0.243) and high-density lipoprotein cholesterol (mean difference = 0.039 mmol L-1 ; 95% CI = 0.024-0.054). The triglyceride-lowering effect was dose-dependent.
Conclusions
The lipid-lowering, hypotensive, anti-arrhythmic and anti-inflammatory actions of EPA and DHA supplements were confirmed in this analysis of randomised placebo-control blinded clinical trials.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.